Mogamulizumab
- Product NameMogamulizumab
- CAS1159266-37-1
- CBNumberCB54845963
- MW0
- EINECS-0
- MOL FileMol file
Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Mogamulizumab Chemical Properties,Usage,Production
Uses
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].in vivo
Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs[4].
| Animal Model: | Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. |
| Result: | Suppressed Tumor growth with vacuolar degeneration. |
IC 50
CCR4References
[1] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4. DOI:10.1177/2040620716636541[2] Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. DOI:10.1158/1078-0432.CCR-14-0580
[3] Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. DOI:10.1093/infdis/jiu438
[4] Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187. DOI:10.1158/2326-6066.CIR-18-0751
Mogamulizumab Suppliers
Global(30)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | 32430 | 58 | ||
| tp@aladdinsci.com | 54731 | 58 | |||
| 6206333 13167063860 | anhua.mao@aladdin-e.com | 49544 | 58 | ||
| 15817493340 | 981810490@qq.com | 1577 | 58 | ||
| 027-65279366 18108604356 | products@biolabreagent.com | 9864 | 58 | ||
| 17316404525 17316404525 | 209533805@qq.com | 9790 | 58 | ||
| 021-65675885 18964387627 | customer_service@efebio.com | 11963 | 58 | ||
| 0573-83568680 18057391398 | 3956524501@qq.com | 1441 | 58 | ||
| 027-65317797 15926423062 | 422450190@qq.com | 10300 | 58 | ||
| 177-54423994 17754423994 | 2853530910@QQ.com | 7999 | 62 |